Trade SAB Biotherapeutics, Inc. - SABS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.65 |
| Open | 2.69 |
| 1-Year Change | 340.98% |
| Day's Range | 2.65 - 2.72 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | 2.72 | 0.03 | 1.12% | 2.69 | 2.72 | 2.62 |
| Sep 12, 2024 | 2.65 | 0.01 | 0.38% | 2.64 | 2.65 | 2.64 |
| Sep 11, 2024 | 2.74 | -0.01 | -0.36% | 2.75 | 2.75 | 2.69 |
| Sep 10, 2024 | 2.65 | 0.00 | 0.00% | 2.65 | 2.66 | 2.63 |
| Sep 9, 2024 | 2.78 | 0.00 | 0.00% | 2.78 | 2.86 | 2.78 |
| Sep 6, 2024 | 2.89 | 0.09 | 3.21% | 2.80 | 2.89 | 2.69 |
| Sep 5, 2024 | 2.77 | -0.05 | -1.77% | 2.82 | 2.82 | 2.76 |
| Sep 4, 2024 | 2.86 | 0.07 | 2.51% | 2.79 | 2.86 | 2.68 |
| Sep 3, 2024 | 2.77 | -0.03 | -1.07% | 2.80 | 2.80 | 2.69 |
| Aug 30, 2024 | 2.89 | 0.09 | 3.21% | 2.80 | 2.89 | 2.75 |
| Aug 29, 2024 | 2.88 | 0.03 | 1.05% | 2.85 | 2.94 | 2.85 |
| Aug 28, 2024 | 2.91 | 0.14 | 5.05% | 2.77 | 2.91 | 2.74 |
| Aug 27, 2024 | 2.45 | -0.09 | -3.54% | 2.54 | 2.58 | 2.43 |
| Aug 26, 2024 | 2.77 | 0.01 | 0.36% | 2.76 | 2.86 | 2.71 |
| Aug 23, 2024 | 2.63 | 0.00 | 0.00% | 2.63 | 2.63 | 2.63 |
| Aug 21, 2024 | 2.63 | 0.05 | 1.94% | 2.58 | 2.68 | 2.58 |
| Aug 20, 2024 | 2.67 | 0.02 | 0.75% | 2.65 | 2.67 | 2.65 |
| Aug 19, 2024 | 2.73 | 0.37 | 15.68% | 2.36 | 2.73 | 2.36 |
| Aug 16, 2024 | 2.38 | 0.13 | 5.78% | 2.25 | 2.43 | 2.25 |
| Aug 15, 2024 | 2.23 | -0.08 | -3.46% | 2.31 | 2.32 | 2.23 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
SAB Biotherapeutics, Inc. Company profile
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.
Financial summary
BRIEF: For the nine months ended 30 September 2021, SAB Biotherapeutics Inc revenues was not reported. Net income totaled to $440K.
| Industry: | Biotechnology & Medical Research (NEC) |
2100 East 54Th Street North
Suite 202
SIOUX FALLS
SOUTH DAKOTA 57104
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com